Theratechnologies starts Phase II insomnia trial

Theratechnologies (TSE:TH) began a placebo-controlled Phase II trial of its ThGRF growth hormone releasing factor peptide analog in 90 patients with sleep maintenance insomnia. The European and Canadi...